Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Malignant Lymphoma

Free Subscription Articles published in Cancer Retrieve available abstracts of 29 articles: HTML format

Single Articles

January 2026
1. YILMAZ U, Dal MS, Ulas T, Atesoglu EB, et al
   Exploring an independent association between rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone dose intensity and clinical outcomes in large B-cell lymphoma: Analyses of subsequent endpoints following a complete response in a real-world
   Cancer. 2026;132:e70248.
   PubMed     Abstract available
   
   
   
2. KONOPLEVA M, Pemmaraju N, Sweet KL, Stein AS, et al
   Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm.
   Cancer. 2026;132:e70243.
   PubMed     Abstract available
   
   
   
3. ZHAO W, Li L, Fu X, Chang Y, et al
   A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma.
   Cancer. 2026;132:e70247.
   PubMed     Abstract available
   
   
   December 2025
4. SHI W, Ren Y, Liu S, Liu Y, et al
   Clinical characteristics and survival outcomes of thymic mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 82 patients.
   Cancer. 2025;131:e70183.
   PubMed     Abstract available
   
   
   September 2025
5. TAN S, He H, Ni J, Guo Y, et al
   Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary ce
   Cancer. 2025;131:e70083.
   PubMed     Abstract available
   
   
   
6. NIERENGARTEN MB
   Safety and promising efficacy with enhanced CAR T-cell therapy for lymphoma.
   Cancer. 2025;131:e70035.
   PubMed    
   
   
   June 2025
7. 
   Correction to "Surveillance imaging during first remission in follicular lymphoma does not impact overall survival".
   Cancer. 2025;131:e35934.
   PubMed    
   
   
   
8. NIERENGARTEN MB
   Ibrutinib plus venetoclax improves progression-free survival in refractory or relapsed mantle cell lymphoma.
   Cancer. 2025;131:e35899.
   PubMed    
   
   
   
9. 
   Correction to "Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study".
   Cancer. 2025;131:e35933.
   PubMed    
   
   
   March 2025
10. RAYCHAUDHURI S, McLaughlin E, Pennell ML, Stefanick M, et al
    The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer.
    Cancer. 2025;131:e35804.
    PubMed     Abstract available
    
    
    
11. JIMENEZ MUNARRIZ BE, Khan S, Li Y, Ghazali N, et al
    Update advances in anaplastic lymphoma kinase-positive non-small cell lung cancer treatment.
    Cancer. 2025;131 Suppl 1:e35786.
    PubMed     Abstract available
    
    
    January 2025
12. YIN X, He Q, Liu D, Xie L, et al
    Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study.
    Cancer. 2025;131:e35697.
    PubMed     Abstract available
    
    
    
13. GAO Y, Huang Y, Zhang Q, Yang H, et al
    Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial.
    Cancer. 2025;131:e35672.
    PubMed     Abstract available
    
    
    November 2024
14. HANZLIK E, Sabin ND, Yoshida T, Delaney A, et al
    Sexual dysfunction among long-term survivors of Hodgkin lymphoma.
    Cancer. 2024 Nov 7. doi: 10.1002/cncr.35637.
    PubMed     Abstract available
    
    
    
15. LI Z, Li X, Li S, Tao R, et al
    Preclinical evaluation and phase 1 study of the PI3Kalpha/delta inhibitor TQ-B3525 in Chinese patients with advanced cancers.
    Cancer. 2024;130:3686-3698.
    PubMed     Abstract available
    
    
    October 2024
16. NIERENGARTEN MB
    Multitargeted therapy is safe and leads to durable remission of DLBCL.
    Cancer. 2024;130:3238.
    PubMed    
    
    
    August 2024
17. ZENG C, Wei Z, Huang J, Zhu J, et al
    Effect of body mass index on the prognosis of children and adolescents with high-grade mature B-cell non-Hodgkin lymphoma.
    Cancer. 2024 Aug 22. doi: 10.1002/cncr.35536.
    PubMed     Abstract available
    
    
    June 2024
18. HSU YT, Wu SJ, Kao HW, Hsiao SY, et al
    Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan.
    Cancer. 2024;130:1972-1981.
    PubMed     Abstract available
    
    
    May 2024
19. LI ZH, Zhang MY, Federico M, Civallero M, et al
    Early histological transformation of follicular lymphoma to diffuse large B-cell lymphoma indicating adverse survival: A population-based analysis and validation.
    Cancer. 2024 May 29. doi: 10.1002/cncr.35378.
    PubMed     Abstract available
    
    
    April 2024
20. NIERENGARTEN MB
    Golidocitinib favorable for relapsed/refractory T-cell lymphoma.
    Cancer. 2024;130:1191-1192.
    PubMed    
    
    
    
21. LI A, Yi H, Deng S, Ruan M, et al
    The genetic landscape of histologically transformed marginal zone lymphomas.
    Cancer. 2024;130:1246-1256.
    PubMed     Abstract available
    
    
    
22. GIRI S, Harmon C, Landier W, Chen Y, et al
    Body composition and late-occurring chronic health conditions after autologous stem cell transplantation for lymphoma.
    Cancer. 2024 Apr 5. doi: 10.1002/cncr.35298.
    PubMed     Abstract available
    
    
    February 2024
23. WU S, Rhee JW, Iukuridze A, Bosworth A, et al
    Coronary artery calcium and cardiovascular outcomes in patients with lymphoma undergoing autologous hematopoietic cell transplantation.
    Cancer. 2024 Feb 15. doi: 10.1002/cncr.35252.
    PubMed     Abstract available
    
    
    
24. TZANKOV A, Tatarczuch M
    Time to Be Launched 1 auXiliary Risk strat1fier in marginal zone lymphoma transformation: TBL1XR1.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35246.
    PubMed    
    
    
    January 2024
25. SEDETA E, Jemal A, Nisotel L, Sung H, et al
    Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
    Cancer. 2024 Jan 20. doi: 10.1002/cncr.35214.
    PubMed     Abstract available
    
    
    December 2023
26. DAI L, Chen H, Tan Q, Wang Y, et al
    Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.
    Cancer. 2023 Dec 22. doi: 10.1002/cncr.35158.
    PubMed     Abstract available
    
    
    
27. CHU Y, Liu Y, Yu Z, Zhan L, et al
    Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta-analysis of randomized trials.
    Cancer. 2023 Dec 2. doi: 10.1002/cncr.35137.
    PubMed     Abstract available
    
    
    November 2023
28. GORDON MJ, Feng L, Strati P, Lee HJ, et al
    Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35114.
    PubMed     Abstract available
    
    
    
29. NIERENGARTEN MB
    New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer. 2023;129:3356.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.